Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
- PMID: 19098898
- PMCID: PMC2895694
- DOI: 10.1038/nbt.1515
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Abstract
Delivery of genes to the brain and spinal cord across the blood-brain barrier (BBB) has not yet been achieved. Here we show that adeno-associated virus (AAV) 9 injected intravenously bypasses the BBB and efficiently targets cells of the central nervous system (CNS). Injection of AAV9-GFP into neonatal mice through the facial vein results in extensive transduction of dorsal root ganglia and motor neurons throughout the spinal cord and widespread transduction of neurons throughout the brain, including the neocortex, hippocampus and cerebellum. In adult mice, tail vein injection of AAV9-GFP leads to robust transduction of astrocytes throughout the entire CNS, with limited neuronal transduction. This approach may enable the development of gene therapies for a range of neurodegenerative diseases, such as spinal muscular atrophy, through targeting of motor neurons, and amyotrophic lateral sclerosis, through targeting of astrocytes. It may also be useful for rapid postnatal genetic manipulations in basic neuroscience studies.
Figures
Comment in
-
Crossing the rubicon.Nat Biotechnol. 2009 Jan;27(1):42-4. doi: 10.1038/nbt0109-42. Nat Biotechnol. 2009. PMID: 19131996 Free PMC article.
-
The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9.Nat Biotechnol. 2009 Sep;27(9):804-5; author reply 805. doi: 10.1038/nbt0909-804. Nat Biotechnol. 2009. PMID: 19741632 No abstract available.
Similar articles
-
Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection.PLoS One. 2017 Dec 15;12(12):e0188830. doi: 10.1371/journal.pone.0188830. eCollection 2017. PLoS One. 2017. PMID: 29244806 Free PMC article.
-
Widespread transduction of astrocytes and neurons in the mouse central nervous system after systemic delivery of a self-complementary AAV-PHP.B vector.Gene Ther. 2018 Apr;25(2):83-92. doi: 10.1038/s41434-018-0005-z. Epub 2018 Mar 9. Gene Ther. 2018. PMID: 29523880
-
Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain.Neurosci Lett. 2018 Feb 5;665:182-188. doi: 10.1016/j.neulet.2017.11.049. Epub 2017 Nov 24. Neurosci Lett. 2018. PMID: 29175632
-
The advent of AAV9 expands applications for brain and spinal cord gene delivery.Expert Opin Biol Ther. 2012 Jun;12(6):757-66. doi: 10.1517/14712598.2012.681463. Epub 2012 Apr 20. Expert Opin Biol Ther. 2012. PMID: 22519910 Free PMC article. Review.
-
Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.Brain Res. 2020 Jul 15;1739:146832. doi: 10.1016/j.brainres.2020.146832. Epub 2020 Apr 11. Brain Res. 2020. PMID: 32289279 Free PMC article. Review.
Cited by
-
Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier.Adv Sci (Weinh). 2021 Aug;8(16):e2101090. doi: 10.1002/advs.202101090. Epub 2021 Jun 3. Adv Sci (Weinh). 2021. PMID: 34085418 Free PMC article. Review.
-
Initial gene vector dosing for studying symptomatology of amyotrophic lateral sclerosis in non-human primates.J Med Primatol. 2015 Apr;44(2):66-75. doi: 10.1111/jmp.12162. Epub 2015 Jan 29. J Med Primatol. 2015. PMID: 25639184 Free PMC article.
-
Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).J Neurosci. 2016 Sep 14;36(37):9669-82. doi: 10.1523/JNEUROSCI.1635-16.2016. J Neurosci. 2016. PMID: 27629717 Free PMC article.
-
Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates.Nat Biomed Eng. 2022 Nov;6(11):1257-1271. doi: 10.1038/s41551-022-00938-7. Epub 2022 Oct 10. Nat Biomed Eng. 2022. PMID: 36217021
-
Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice.Mol Ther Methods Clin Dev. 2015 Mar 25;2:15007. doi: 10.1038/mtm.2015.7. eCollection 2015. Mol Ther Methods Clin Dev. 2015. PMID: 26029718 Free PMC article.
References
-
- Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov. 2002;1:131–139. - PubMed
-
- Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301:839–842. - PubMed
-
- Azzouz M, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429:413–417. - PubMed
-
- Ralph GS, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med. 2005;11:429–433. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources